{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T13:22:10Z","timestamp":1764163330282,"version":"3.46.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,26]]},"DOI":"10.7759\/cureus.97849","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T13:16:55Z","timestamp":1764163015000},"source":"Crossref","is-referenced-by-count":0,"title":["Tumor Necrosis Factor (TNF)-Alpha Inhibitors in Hidradenitis Suppurativa: A Systematic Review of Inflammatory Markers and Alternative Monitoring Strategies"],"prefix":"10.7759","author":[{"given":"Rupanshu","family":"R","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russaal S","family":"Mann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isha","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Kilic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayushi","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bilal","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safeera","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02475-9","article-title":"Hidradenitis suppurativa","volume":"405","author":"Sabat R","year":"2025","unstructured":"Sabat R, Alavi A, Wolk K, et al.. Hidradenitis suppurativa. The Lancet. 2025, 405:420-438. 10.1016\/S0140-6736(24)02475-9","journal-title":"The Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073753","article-title":"New and emerging targeted therapies for hidradenitis suppurativa","volume":"23","author":"Markota \u010cagalj A","year":"2022","unstructured":"Markota \u010cagalj A, Marinovi\u0107 B, Bukvi\u0107 Mokos Z. New and emerging targeted therapies for hidradenitis suppurativa. Int J Mol Sci. 2022, 23:10.3390\/ijms23073753","journal-title":"Int J Mol Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/12034754241300292","article-title":"Hidradenitis suppurativa: a review of the biologic and small molecule immunomodulatory treatments","volume":"29","author":"Chiang N","year":"2025","unstructured":"Chiang N, Alhusayen R. Hidradenitis suppurativa: a review of the biologic and small molecule immunomodulatory treatments. J Cutan Med Surg. 2025, 29:NP1-NP20. 10.1177\/12034754241300292","journal-title":"J Cutan Med Surg"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.24755","article-title":"Hidradenitis suppurativa in the United States: insights from the national inpatient sample (2008-2017) on contemporary trends in demographics, hospitalization rates, chronic comorbid conditions, and mortality","volume":"14","author":"Patel A","year":"2022","unstructured":"Patel A, Patel A, Solanki D, et al.. Hidradenitis suppurativa in the United States: insights from the national inpatient sample (2008-2017) on contemporary trends in demographics, hospitalization rates, chronic comorbid conditions, and mortality. Cureus. 2022, 14:e24755. 10.7759\/cureus.24755","journal-title":"Cureus"},{"key":"ref5","unstructured":"bioRender. Homepage. (2025). Accessed: November 26, 2025: http:\/\/BioRender.com.."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea BJ","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al.. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017, 358:j4008. 10.1136\/bmj.j4008","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16835","article-title":"Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: A 52-week analysis of a postmarketing surveillance study in Japan","volume":"50","author":"Hayashi N","year":"2023","unstructured":"Hayashi N, Hayama K, Takahashi K, et al.. Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: A 52-week analysis of a postmarketing surveillance study in Japan. J Dermatol. 2023, 50:1034-44. 10.1111\/1346-8138.16835","journal-title":"J Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16297","article-title":"Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12-week interim analysis of post-marketing surveillance in Japan","volume":"49","author":"Hayashi N","year":"2022","unstructured":"Hayashi N, Hayama K, Takahashi K, et al.. Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12-week interim analysis of post-marketing surveillance in Japan. J Dermatol. 2022, 49:411-21. 10.1111\/1346-8138.16297","journal-title":"J Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17598","article-title":"Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study","volume":"35","author":"Gulliver W","year":"2021","unstructured":"Gulliver W, Alavi A, Wiseman MC, et al.. Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study. J Eur Acad Dermatol Venereol. 2021, 35:2431-9. 10.1111\/jdv.17598","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17551","article-title":"Improvement in Hidradenitis Suppurativa and quality of life in patients treated with adalimumab: real-world results from the HARMONY study","volume":"35","author":"Hafner A","year":"2021","unstructured":"Hafner A, Ghislain PD, Kov\u00e1cs R, et al.. Improvement in Hidradenitis Suppurativa and quality of life in patients treated with adalimumab: real-world results from the HARMONY study. J Eur Acad Dermatol Venereol. 2021, 35:2277-84. 10.1111\/jdv.17551","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.6868","article-title":"Increased doses of adalimumab are associated with clinical improvement of hidradenitis suppurativa","volume":"22","author":"Williams J","year":"2023","unstructured":"Williams J, Guzik C, Wadhera A, Naik H. Increased doses of adalimumab are associated with clinical improvement of hidradenitis suppurativa. J Drugs Dermatol. 2023, 22:615-8. 10.36849\/JDD.6868","journal-title":"J Drugs Dermatol"},{"key":"ref13","article-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells GA","unstructured":"Wells GA, Shea B, O\u2019Connell D, et al.. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026190","article-title":"Efficacy and safety of adalimumab in hidradenitis suppurativa: A systematic review and meta-analysis of randomized controlled trials","volume":"100","author":"Lu JW","year":"2021","unstructured":"Lu JW, Huang YW, Chen TL. Efficacy and safety of adalimumab in hidradenitis suppurativa: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2021, 100:e26190. 10.1097\/MD.0000000000026190","journal-title":"Medicine (Baltimore)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2022.04.005","article-title":"Erythrocyte sedimentation rate, rather than C-reactive protein, may be the preferred biomarker for hidradenitis suppurativa","volume":"8","author":"Gibson RS","year":"2022","unstructured":"Gibson RS, Porter ML, Kimball AB. Erythrocyte sedimentation rate, rather than C-reactive protein, may be the preferred biomarker for hidradenitis suppurativa. JAAD Int. 2022, 8:47-8. 10.1016\/j.jdin.2022.04.005","journal-title":"JAAD Int"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3012","article-title":"Achieving hidradenitis suppurativa response score is associated with significant improvement in clinical and patient-reported outcomes: post hoc analysis of pooled data from PIONEER I and II","volume":"98","author":"Kimball AB","year":"2018","unstructured":"Kimball AB, Tzellos T, Calimlim BM, et al..  Achieving hidradenitis suppurativa response score is associated with significant improvement in clinical and patient-reported outcomes: post hoc analysis of pooled data from PIONEER I and II. Acta Derm Venereol. 2018, 98:932-7. 10.2340\/00015555-3012","journal-title":"Acta Derm Venereol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24098428","article-title":"New insight into the molecular pathomechanism and immunomodulatory treatments of hidradenitis suppurativa","volume":"24","author":"Molinelli E","year":"2023","unstructured":"Molinelli E, Gioacchini H, Sapigni C, et al.. New insight into the molecular pathomechanism and immunomodulatory treatments of hidradenitis suppurativa. Int J Mol Sci. 2023, 24:10.3390\/ijms24098428","journal-title":"Int J Mol Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17741","article-title":"Refining how we measure as we test: new insights using adalimumab in patients with hidradenitis suppurativa","volume":"35","author":"Gibson RS","year":"2021","unstructured":"Gibson RS, Kimball AB. Refining how we measure as we test: new insights using adalimumab in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2021, 35:2342. 10.1111\/jdv.17741","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/417873-tumor-necrosis-factor-tnf-alpha-inhibitors-in-hidradenitis-suppurativa-a-systematic-review-of-inflammatory-markers-and-alternative-monitoring-strategies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T13:16:57Z","timestamp":1764163017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/417873-tumor-necrosis-factor-tnf-alpha-inhibitors-in-hidradenitis-suppurativa-a-systematic-review-of-inflammatory-markers-and-alternative-monitoring-strategies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.97849","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,26]]}}}